Courtesy: red hotThursday, July 23, 2009
Tuesday, July 21, 2009
India Heads High on Neem Patent Saga - Patent Analytics Report
A new study by Dolcera has confirmed that India has indeed lived up to the competitive neem research and development efforts from the West.
A new study by Dolcera has confirmed that India has indeed lived up to the competitive neem research and development efforts from the West. Neem is considered India’s heritage and an integral part of India’s culture. Neem has traditionally been used as an ingredient in Indian cuisine, as a medicinal treatment for several allergies and diseases, and in religious ceremoniesacross the country. Time and again, there has been a hue and cry to prevent other countries from patenting the age-old Indian knowledge of neem.
Dolcera’s study has answers to key questions, including:
• Are Indians holding a legal upper hand on neem usage?
• What are the neem patenting trends in India and the US?
The study also reveals that the Council for Scientific and Industrial Research (CSIR), India, played a key role in India as well as in the US to remain one of the top patent owners in terms of number of patent filings on applications of neem. However, the complete picture is a little more complicated. Though CSIR is the top patent owner, individuals (41.84%) and private sector (31.63%) hold the majority of neem patents in India. Government institutes (which include CSIR, the Defense Research and Development Organization, and others) hold 26.53% of patents on India’s traditional asset.
While Indians have used neem for medicinal purposes in wound healing, diabetes, HIV/AIDS and skin care, US companies appear more interested in the areas of biodiesel production, fertilizers, dental formulations, food packaging, pharmaceutical compositions, etc.
Courtesy : LIVE-PR
A new study by Dolcera has confirmed that India has indeed lived up to the competitive neem research and development efforts from the West. Neem is considered India’s heritage and an integral part of India’s culture. Neem has traditionally been used as an ingredient in Indian cuisine, as a medicinal treatment for several allergies and diseases, and in religious ceremoniesacross the country. Time and again, there has been a hue and cry to prevent other countries from patenting the age-old Indian knowledge of neem.
Dolcera’s study has answers to key questions, including:
• Are Indians holding a legal upper hand on neem usage?
• What are the neem patenting trends in India and the US?
The study also reveals that the Council for Scientific and Industrial Research (CSIR), India, played a key role in India as well as in the US to remain one of the top patent owners in terms of number of patent filings on applications of neem. However, the complete picture is a little more complicated. Though CSIR is the top patent owner, individuals (41.84%) and private sector (31.63%) hold the majority of neem patents in India. Government institutes (which include CSIR, the Defense Research and Development Organization, and others) hold 26.53% of patents on India’s traditional asset.
While Indians have used neem for medicinal purposes in wound healing, diabetes, HIV/AIDS and skin care, US companies appear more interested in the areas of biodiesel production, fertilizers, dental formulations, food packaging, pharmaceutical compositions, etc.
Courtesy : LIVE-PR
Sunday, July 19, 2009
Union Audit Reports Scientific Departments (Compliance Audit - Report No. 16 of 2008-09) 2007-2008
Total report here
Saturday, July 18, 2009
Banks face fines for ATM errors
MUMBAI: Banks will now have to pay account holders a compensation of Rs 100 per day for every day of delay in reversing in failed transactions.
The Reserve Bank of India (RBI) has imposed stringent penalties on banks who fail to reverse a transaction where cash is not dispensed by the ATM but the customer’s account gets debited within 12 days.
In a circular issued on Friday, RBI has said banks must re-credit such customers’ accounts within 12 working days from the date of receipt of the complaint.
The circular is in response to complaints from customers who had to put up with delays in getting back money erroneously debited during failed ATM transactions. Besides imposing the stiff penalty, the central bank also made it clear that this amount needs to be credited to the customer’s account automatically on the day of the re-credit without the customer having to make a claim.
In case the delay is because of a third-party bank ATM through which the customer has transacted, the card-issuing bank must still pay the penalty to the customer. However, it will recover this amount from the bank that owns the ATM.
Similarly, if a non-bank network operator is the reason behind the delay, the bank will make the payment and recover the penalty from the operator.
Furthermore, the RBI has instructed banks to extend the scope of concurrent audit to cover cases of such delays. Banks are now also required to place a quarterly review of ATM transactions to its board of directors, indicating the quantum of penalties paid, reasons for the same, and the remedial action taken to prevent the recurrence of such cases. A copy will have to be forwarded to the central bank.
This apart, the Reserve Bank made a critical note of different banks setting different cutoff limits for permitting cash withdrawals from/for other bank customers.
Courtesy: Economic times
The Reserve Bank of India (RBI) has imposed stringent penalties on banks who fail to reverse a transaction where cash is not dispensed by the ATM but the customer’s account gets debited within 12 days.
In a circular issued on Friday, RBI has said banks must re-credit such customers’ accounts within 12 working days from the date of receipt of the complaint.
The circular is in response to complaints from customers who had to put up with delays in getting back money erroneously debited during failed ATM transactions. Besides imposing the stiff penalty, the central bank also made it clear that this amount needs to be credited to the customer’s account automatically on the day of the re-credit without the customer having to make a claim.
In case the delay is because of a third-party bank ATM through which the customer has transacted, the card-issuing bank must still pay the penalty to the customer. However, it will recover this amount from the bank that owns the ATM.
Similarly, if a non-bank network operator is the reason behind the delay, the bank will make the payment and recover the penalty from the operator.
Furthermore, the RBI has instructed banks to extend the scope of concurrent audit to cover cases of such delays. Banks are now also required to place a quarterly review of ATM transactions to its board of directors, indicating the quantum of penalties paid, reasons for the same, and the remedial action taken to prevent the recurrence of such cases. A copy will have to be forwarded to the central bank.
This apart, the Reserve Bank made a critical note of different banks setting different cutoff limits for permitting cash withdrawals from/for other bank customers.
Courtesy: Economic times
Thursday, July 16, 2009
Wednesday, July 15, 2009
Review of CGHS
The performance of the CGHS is regularly reviewed by the Government. The Committee of Secretaries has also been regularly reviewing the functioning of the CGHS since December, 2008, and has been giving directions to the Ministry of Health & Family Welfare for making it beneficiary friendly. Some of the recent initiatives are listed below:
(1) Extension of CGHS: CGHS today covers 24 cities, apart from Delhi. Dehradun, Ranchi, Bhubaneshwar and Jammu are the cities where CGHS was extended during the last four years. (2) Computerization: To keep pace with the modern times, a massive computerisation work has been taken up under CGHS in collaboration with the National Informatics Centre. Computerization of the CGHS will result in lesser waiting period for beneficiaries at the dispensaries; on-line placement of indents on local chemists; availability of patient profiles;
availability of medicines / drugs usage pattern, which will enable the CGHS to prepare a realistic list of formulary drugs; reduction in use of paper; removal of jurisdictional restriction (as regards the dispensary) for the beneficiaries, etc.
(3) Introduction of Plastic Cards: As part of the computerisation process, it has been decided to issue plastic cards individually to each beneficiary of the CGHS. This will enable beneficiaries to avail CGHS facility in any city should they happen to be in that city either on official work or on leave. Inter-city treatment will be possible after all cities are computerised and networked.
(4) Accreditation of labs with National Accreditation Board for Testing and Calibration Laboratories (NABL) :
With a view to providing better quality treatment to CGHS beneficiaries, it was decided that only those private hospitals and diagnostic centres would be empanelled under the CGHS, as have been cleared by the Quality Council of India after it carried out inspection of the facilities available at these hospitals and diagnostic centres. It has also been decided that all the laboratories on the panel of CGHS have to get certificate issued by the NABL under the Quality Council of India.
(5) Medical Audit of Hospital Bills is an important exercise to assess the quality of services offered and expenditure incurred. In order to be sure that the bills raised by private empanelled hospitals are genuine and that the beneficiaries were required to undergo only that treatment as was required and that the hospital has not forced the beneficiary to undergo unnecessary tests / treatment at the hospital. The job of medical audit of Hospital bills has been outsourced to TPAs.
(6) Holding of Claims Adalats: Complaints were received in the CGHS and in the Ministry that old cases of reimbursement of medical expenses incurred by pensioners were pending for settlement for long time. It was decided that claims adalats be held in each Zonal office of CGHS, Delhi, under the chairmanship of the Additional Directors of the respective zones. Claims adalats were held annually, in each zone (East, Central, South and North Zones) in Delhi, during 2007 and 2008 and over 95% of the claims were settled in those adalats.
(7) Local Advisory Committees: Local Advisory Committee meetings are held in each CGHS dispensary on second Saturday of the month, which is attended by Area Welfare Officer appointed by the Chief Welfare Officer, Department of Personnel & Training, representatives from pensioners’ association, local chemist to resolve problems at dispensary level.
(8) Decentralisation and delegation of powers: Ministries / Departments have been delegated powers to handle all cases of reimbursement claims if no relaxation of rules was involved. Earlier they had powers to handle requests upto Rupees two lakhs and beyond that amount, the cases were referred to CGHS.
(9) Insulin: Orders have been issued to permit issue of Analogue (Insulin Vial/Cartridge) to CGHS beneficiaries and the extra cost would be borne by the CGHS. The beneficiaries would have to purchase the pen for utilization the analogue insulin.
(10) Outsourcing of cleaning process of dispensaries: As there were shortage of Class IV Staff in a large number of dispensaries in Delhi, it was decided to relocate Class IV staff from a few deficient dispensaries to other deficient dispensaries. To overcome the vacuum so created in some dispensaries, it was decided to outsource cleaning work for mechanised cleaning. The agency has been handling this work for the last five months, and the work done by them has been appreciated by all.
(11) Rate contract for purchase of drugs: It has been decided to run a pilot project under which dispensaries in Delhi will be permitted to place indents directly on the manufacturers on rate contract basis. If the proposal proves to be a success, then it may be extended to cover the entire CGHS. The benefit of this arrangement is that dispensaries / CGHS do not have to carry huge inventory of medicines and indents can be placed on a monthly basis depending on the need.
The Sixth Central Pay Commission recommended the introduction of health insurance scheme for Central Government employees and pensioners. It had recommended that for existing employees and pensioners, the scheme should be available on the voluntary basis, subject to their paying prescribed contribution. It has also recommended that the health insurance scheme should be compulsory for new Government employees who would be joining service after the introduction of the scheme. Similarly, it had recommended that new retirees, after the introduction of the insurance would be covered under the scheme.
An expression of interest has been floated by the Ministry of Health & Family Welfare inviting suggestions from insurance companies providing health insurance and health consultants on the structure, feasibility and viability of such a scheme.
This information was given by Shri Ghulam Nabi Azad, Union Minister for Health & Family Welfare in a written reply to a question in the Lok Sabha today.
(1) Extension of CGHS: CGHS today covers 24 cities, apart from Delhi. Dehradun, Ranchi, Bhubaneshwar and Jammu are the cities where CGHS was extended during the last four years. (2) Computerization: To keep pace with the modern times, a massive computerisation work has been taken up under CGHS in collaboration with the National Informatics Centre. Computerization of the CGHS will result in lesser waiting period for beneficiaries at the dispensaries; on-line placement of indents on local chemists; availability of patient profiles;
availability of medicines / drugs usage pattern, which will enable the CGHS to prepare a realistic list of formulary drugs; reduction in use of paper; removal of jurisdictional restriction (as regards the dispensary) for the beneficiaries, etc.(3) Introduction of Plastic Cards: As part of the computerisation process, it has been decided to issue plastic cards individually to each beneficiary of the CGHS. This will enable beneficiaries to avail CGHS facility in any city should they happen to be in that city either on official work or on leave. Inter-city treatment will be possible after all cities are computerised and networked.
(4) Accreditation of labs with National Accreditation Board for Testing and Calibration Laboratories (NABL) :
With a view to providing better quality treatment to CGHS beneficiaries, it was decided that only those private hospitals and diagnostic centres would be empanelled under the CGHS, as have been cleared by the Quality Council of India after it carried out inspection of the facilities available at these hospitals and diagnostic centres. It has also been decided that all the laboratories on the panel of CGHS have to get certificate issued by the NABL under the Quality Council of India.
(5) Medical Audit of Hospital Bills is an important exercise to assess the quality of services offered and expenditure incurred. In order to be sure that the bills raised by private empanelled hospitals are genuine and that the beneficiaries were required to undergo only that treatment as was required and that the hospital has not forced the beneficiary to undergo unnecessary tests / treatment at the hospital. The job of medical audit of Hospital bills has been outsourced to TPAs.
(6) Holding of Claims Adalats: Complaints were received in the CGHS and in the Ministry that old cases of reimbursement of medical expenses incurred by pensioners were pending for settlement for long time. It was decided that claims adalats be held in each Zonal office of CGHS, Delhi, under the chairmanship of the Additional Directors of the respective zones. Claims adalats were held annually, in each zone (East, Central, South and North Zones) in Delhi, during 2007 and 2008 and over 95% of the claims were settled in those adalats.
(7) Local Advisory Committees: Local Advisory Committee meetings are held in each CGHS dispensary on second Saturday of the month, which is attended by Area Welfare Officer appointed by the Chief Welfare Officer, Department of Personnel & Training, representatives from pensioners’ association, local chemist to resolve problems at dispensary level.
(8) Decentralisation and delegation of powers: Ministries / Departments have been delegated powers to handle all cases of reimbursement claims if no relaxation of rules was involved. Earlier they had powers to handle requests upto Rupees two lakhs and beyond that amount, the cases were referred to CGHS.
(9) Insulin: Orders have been issued to permit issue of Analogue (Insulin Vial/Cartridge) to CGHS beneficiaries and the extra cost would be borne by the CGHS. The beneficiaries would have to purchase the pen for utilization the analogue insulin.
(10) Outsourcing of cleaning process of dispensaries: As there were shortage of Class IV Staff in a large number of dispensaries in Delhi, it was decided to relocate Class IV staff from a few deficient dispensaries to other deficient dispensaries. To overcome the vacuum so created in some dispensaries, it was decided to outsource cleaning work for mechanised cleaning. The agency has been handling this work for the last five months, and the work done by them has been appreciated by all.
(11) Rate contract for purchase of drugs: It has been decided to run a pilot project under which dispensaries in Delhi will be permitted to place indents directly on the manufacturers on rate contract basis. If the proposal proves to be a success, then it may be extended to cover the entire CGHS. The benefit of this arrangement is that dispensaries / CGHS do not have to carry huge inventory of medicines and indents can be placed on a monthly basis depending on the need.
The Sixth Central Pay Commission recommended the introduction of health insurance scheme for Central Government employees and pensioners. It had recommended that for existing employees and pensioners, the scheme should be available on the voluntary basis, subject to their paying prescribed contribution. It has also recommended that the health insurance scheme should be compulsory for new Government employees who would be joining service after the introduction of the scheme. Similarly, it had recommended that new retirees, after the introduction of the insurance would be covered under the scheme.
An expression of interest has been floated by the Ministry of Health & Family Welfare inviting suggestions from insurance companies providing health insurance and health consultants on the structure, feasibility and viability of such a scheme.
This information was given by Shri Ghulam Nabi Azad, Union Minister for Health & Family Welfare in a written reply to a question in the Lok Sabha today.
Tuesday, July 14, 2009
Monday, July 13, 2009
Sunday, July 12, 2009
Scientist develop solar powered rickshaw
Kolkata (PTI): Weary rickshaw pullers will no longer have to toil to pedal the vehicle as scientists of CSIR's Central Mechanical and Engineering Research Institute (CMERI) have developed a solar electric rickshaw.
Named Soleckshaw, the solar electric rickshaw is a pollution-free, safe and economical solution to the woes of around 50 lakh rickshaw pullers in the country.
"The goal was to develop an optimally-designed, pedal-operated and motor-assisted, zero-carbon emission, urban transport vehicle," Tech Review quotes Samir K Brahmachari, Director General of CSIR as saying.
The new pedicab with a seating capacity for two to three passengers and a payload of 150-200 kgs, excluding the driver, will run at a speed of 15 km per hour. It can be driven for as much as 40 kms.
The new rickshaw is motor-assisted and therefore is likely to be driven easily both in the plains and the hills.
"One of the main aims of Soleckshaw is to reduce the effort required to pull a rickshaw. The 36V motor has been used to 'assist' the driver in pedaling. Even though it may not relieve him of pedaling, it will definitely make the task almost effortless for him," says Project Advisor Gopal Sinha.
While the driver's seat is adjustable and a suspension system ensures smooth ride, all the three wheels have brakes.
The new pedicab comes with features such as a head light, a tail lamp, and indicators. A lower foot board provides easy access for children, senior citizens and the disabled.
Courtesy: The Hindu
Courtesy: The Hindu
Safety rider to disabled posts
New Delhi, July 11: A person can be denied promotion if he has a disability that makes him unfit to carry out his job in a higher post or poses a safety risk, the Supreme Court has ruled.
The court, however, made it clear that a disability in itself cannot bar a person from promotion, as laid down by the disabilities act of 1995.
However, the court added that the act was not intended to jeopardise the safety of the public, the disabled employee himself or his co-employees, or the safety of the employers’ equipment or assets. Nor was the law aimed at accepting reduced standards of safety and efficiency merely because an employee suffered from a disability.
“If promotion is denied on the ground it will affect safety, security and performance, then it is not denial of promotion merely on the ground of disability but is denial by reason of the disability plus something more, i.e. (an) adverse effect upon (the) employee’s performance of (the) higher duties or functions attached to the promotional post,” a two-judge bench said on Thursday.
The court was ruling on a railway ministry appeal against a high court decision asking it to promote a colour-blind person to a higher grade.
Devender Kumar Pant was appointed lab assistant in the Research Designs and Standards Organisation (RDSO) in 1972. He was promoted to junior research assistant in 1977 and senior research assistant in 1983.
In 1997, the ministry promoted him to chief research assistant on condition he get a medical certificate stating he was not colour blind. Pant moved the Lucknow bench of the Central Administrative Tribunal, asking it to quash the part of the order requiring him to produce the certificate, and other orders asking him to appear before medical officers.
The tribunal dismissed his case in May 2005, ruling that the ministry order was in keeping with job requirements and was in his own interest and that of other employees. It held that unless Pant obtained the fitness certificate, he would not be meeting the medical standards for the post.
Allahabad High Court, however, upheld Pant’s appeal, ruling that promotion could not be denied merely on the ground of disability unless the employer was exempted from certain provisions of the 1995 act by a notification. No such notification exempted the RDSO.
The Supreme Court, upholding the ministry appeal, also noted that the law often treated people with different disabilities differently.
For example, a provision of the act reserves jobs for people with blindness, low vision, hearing impairment, locomotor disability or cerebral palsy, but not for those with mental retardation or illness.
The court also said that colour blindness could not be construed as a disability under the 1995 Act, since it did not amount to blindness or low vision. So, it was doubtful whether a colour-blind person could claim benefits under the act.
Courtesy: The Telegraph
Saturday, July 11, 2009
Health Insurance for Government Employees
The Sixth Central Pay Commission recommended the introduction of health insurance scheme for Central Government Employees and pensioners. It had recommended that for existing employees and pensioners, the scheme should be available on a voluntary basis subject to their paying prescribed contribution. It had also recommended that the health scheme should be compulsory for new Government employees who would be joining service after the introduction of the Scheme. Similarly, it had recommended that new retirees after the introduction of the insurance scheme would be covered under the scheme.
Ministry of Health & Family Welfare has floated an Expression of Interest from Insurance companies providing health insurance and health insurance Consultants for implementation of the proposed Central Government Employees and Pensioners Health Insurance Scheme (CGEPHIS) for Central Government employees and pensioners on an all India basis.
This information was given by Shri Ghulam Nabi Azad, Union Minister for Health & Family Welfare in a written reply to a question in the Rajya Sabha today.
see my earlier post for detail here
Ministry of Health & Family Welfare has floated an Expression of Interest from Insurance companies providing health insurance and health insurance Consultants for implementation of the proposed Central Government Employees and Pensioners Health Insurance Scheme (CGEPHIS) for Central Government employees and pensioners on an all India basis.
This information was given by Shri Ghulam Nabi Azad, Union Minister for Health & Family Welfare in a written reply to a question in the Rajya Sabha today.
see my earlier post for detail here
Streptokinase, A Life Saving Drug, Developed in collaboration with CSIR launched for Indian Market
Shri Prithviraj Chavan, Minister of State for Science and Technology and Earth Sciences (IC), PMO, Personnel, Public Grievances & Pensions and Parliamentary Affairs, today announced the launch of Streptokinase, a life saver, for marketing in India. Streptokinase is an effective and inexpensive clot dissolving drug used in the treatment of myocardial infarction and pulmonary embolism and belongs to the category of fibrinolytics/clot busters which work by activating plasminogen to produce plasmin which in turn helps in dissolving the clot.
The technology for this life-saver drug was developed at the Chandigarh based Institute of Microbial Technology, a constituent laboratory of Council of Scientific & Industrial Research (CSIR). Chennai based Pharma major Shasun Chemicals and Drugs is making a foray into Biotherapeutics by launching Streptokinase in the Indian Market.
Speaking on the occasion, Shri Prithviraj Chavan termed the launch as classic example of what public funded R&D can do. Lauding the efforts of the scientists he said that laboratories and markets must work in an environment of mutual respect to benefit the society. The Minister also expressed hope that CSIR will rededicate itself to make a difference to the life of common man.
Prof. Samir. K. Brahmachari, Director General, CSIR and Mr N. Govindarajan, CEO & MD, Shasun Chemicals & Drugs Ltd. were among those present during the launch.
The technology for the synthesis of this therapeutic protein was developed at Institute of Microbial technology (IMTech) by Dr. Girish Sahni, Director IMTech and his team, including Drs. Deb Sahoo and Kanak Dikshit. IMTech is a premier institute working on the frontiers of Science and Technology under the auspices of the Council of Scientific and Industrial research (CSIR), Government of India. Once developed, the technology was licensed to Shasun Chemicals and Drugs (Shasun) in the year 2002 and Shasun had undertaken enormous amounts of work to effect the transition of this technology from the labs in IMTech to the commercial market place. IMTech, through their guidance on the nuances of the technology, played a pivotal role in the commercialization of this technology. This development represents and endorses the importance of Public-Private-Partnerships to produce affordable medicines.
Over the last decade, treatment mechanism for patients with AMI (Acute Myocardial Infarction) has been by intravenous thrombolysis using Streptokinase. This mode of treatment makes it highly critical for the medicine to be of absolutely best purity. The Streptokinase developed being a recombinant protein does not have any traces of Streptolysin or Streptodornase (which are usually harmful) associated with natural streptokinase. Further studies in the lab have also demonstrated that Shasun’s Streptokinase has one of the best fibrinolytic activities amongst the products currently available in the market.
This medicine will provide immense benefit to the Indian population by reducing mortality among patients, increasing lifespan among the younger generation (young patients with fewer clots can be treated and they are safe for ~ 10 years) and in case of early thrombolytic treatment will avoid surgery and the huge expenses involved in surgical intervention. The medicine is highly affordable and eliminates the need for tPA which is highly expensive.
IMTech, it may be recalled, had also licensed an improved, new clot-specific thrombolytic to Nostrum Inc., USA and Symmetrix Biotech, India recently. This drug is undergoing regulatory testing and is expected to be commercialized in the year 2011.
The technology for this life-saver drug was developed at the Chandigarh based Institute of Microbial Technology, a constituent laboratory of Council of Scientific & Industrial Research (CSIR). Chennai based Pharma major Shasun Chemicals and Drugs is making a foray into Biotherapeutics by launching Streptokinase in the Indian Market.
Speaking on the occasion, Shri Prithviraj Chavan termed the launch as classic example of what public funded R&D can do. Lauding the efforts of the scientists he said that laboratories and markets must work in an environment of mutual respect to benefit the society. The Minister also expressed hope that CSIR will rededicate itself to make a difference to the life of common man.
Prof. Samir. K. Brahmachari, Director General, CSIR and Mr N. Govindarajan, CEO & MD, Shasun Chemicals & Drugs Ltd. were among those present during the launch.
The technology for the synthesis of this therapeutic protein was developed at Institute of Microbial technology (IMTech) by Dr. Girish Sahni, Director IMTech and his team, including Drs. Deb Sahoo and Kanak Dikshit. IMTech is a premier institute working on the frontiers of Science and Technology under the auspices of the Council of Scientific and Industrial research (CSIR), Government of India. Once developed, the technology was licensed to Shasun Chemicals and Drugs (Shasun) in the year 2002 and Shasun had undertaken enormous amounts of work to effect the transition of this technology from the labs in IMTech to the commercial market place. IMTech, through their guidance on the nuances of the technology, played a pivotal role in the commercialization of this technology. This development represents and endorses the importance of Public-Private-Partnerships to produce affordable medicines.
Over the last decade, treatment mechanism for patients with AMI (Acute Myocardial Infarction) has been by intravenous thrombolysis using Streptokinase. This mode of treatment makes it highly critical for the medicine to be of absolutely best purity. The Streptokinase developed being a recombinant protein does not have any traces of Streptolysin or Streptodornase (which are usually harmful) associated with natural streptokinase. Further studies in the lab have also demonstrated that Shasun’s Streptokinase has one of the best fibrinolytic activities amongst the products currently available in the market.
This medicine will provide immense benefit to the Indian population by reducing mortality among patients, increasing lifespan among the younger generation (young patients with fewer clots can be treated and they are safe for ~ 10 years) and in case of early thrombolytic treatment will avoid surgery and the huge expenses involved in surgical intervention. The medicine is highly affordable and eliminates the need for tPA which is highly expensive.
IMTech, it may be recalled, had also licensed an improved, new clot-specific thrombolytic to Nostrum Inc., USA and Symmetrix Biotech, India recently. This drug is undergoing regulatory testing and is expected to be commercialized in the year 2011.
Subscribe to:
Posts (Atom)